HOME >> MEDICINE >> NEWS
Study documents decline in rare paralytic disorder linked to influenza vaccination

The number of reported cases of Gillain-Barre syndrome (a rare paralytic disorder) that occur following influenza vaccination has decreased over the past 12 years, according to a study in the November 24 issue of JAMA.

Guillain-Barr syndrome (GBS) is a paralytic disorder in which the body's immune system affects part of the peripheral nervous system, according to background information in the article. The first symptoms include varying degrees of weakness or tingling sensations in the legs followed by progressive weakness. Concerns about the risk of developing GBS following influenza vaccination have been present since an association was first noticed during the 1976-1977 A/New Jersey ("swine influenza") season. Evidence for a relationship between GBS and other influenza vaccines, however, has been less clear. GBS remains the most frequent neurological condition reported after influenza vaccination to the Vaccine Adverse Events Reporting System (VAERS) since its inception in 1990.

Penina Haber, M.P.H., of the Centers for Disease Control and Prevention, Atlanta, and colleagues evaluated trends of reports to VAERS of GBS following influenza vaccination in adults. Reports of GBS in persons 18 years or older following influenza vaccination were evaluated for each influenza season from July 1, 1990, through June 30, 2003. The number of people vaccinated was estimated from the National Health Interview Survey and U.S. census data. Beginning in 1994, active follow-up was conducted to verify GBS diagnosis and obtain other clinical details.

The researchers found that from July 1990 through June 2003, VAERS received 501 reports of GBS following influenza vaccination in persons at least 18 years old. Annual reporting rates of GBS per 100, 000 influenza vaccinations declined from a high of 0.17 in 1993-1994 to a low of 0.04 in 2002-2003, a 4-fold decrease. A GBS diagnosis was confirmed in 82 percent of reports. Preceding illness within 4 weeks of vacc
'"/>

Contact: CDCs Press Office
404-639-3286
JAMA and Archives Journals
23-Nov-2004


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:5/22/2015)... The world is at a "hinge ... to create new opportunities for leadership in health ... WesternU's 34th annual Commencement Exercises said Wednesday, May ... former San Francisco mayor and likely 2018 gubernatorial ... ceremony for WesternU's colleges of Allied Health Professions ...
(Date:5/22/2015)... The American College of Traditional Chinese Medicine ... will hold a webinar on the updates of the ... Classical Chinese Medicine. , Webinar – First Professional Doctorate ... Dean of Clinical Education, will lead this webinar in ... program. ACTCM is currently developing this degree program based ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health Limited ... brand Nature’s Way, Marc St-Onge has affirmed his commitment ... is an integral part of the agreement with Nature’s ... further develop Ascenta Skin into a leading player in ... breakthrough, anti-aging skincare supplement featuring 6 active ingredients including ...
(Date:5/22/2015)... UK (PRWEB) May 22, 2015 ... leading treatment option for chronic obstructive pulmonary disorder ... GlaxoSmithKline plc and AstraZeneca plc as well as ... market share and position. But will market payers, ... the already well-entrenched products to completely new ones? ...
Breaking Medicine News(10 mins):Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2
(Date:5/22/2015)...  BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading ... storage and cryopreservation freeze media and ... or the "Company"), announced that the Company is scheduled to ... The Company is scheduled to present at the Conference at ... Grand Hyatt Hotel in New York City ...
(Date:5/22/2015)... , May 22, 2015 The ... the $13 billion global cardiac rhythm management device ... Kalorama found that Medtronic, St. Jude Medical, Boston ... 80% of this market segment. The healthcare market ... Markets , uses 2015 as a base year, ...
(Date:5/22/2015)... , May 22, 2015  The U.S. Food ... (filgrastim-sndz) -- the first biosimilar product approved in ... points toward growth in the contract manufacturing organization ... CMO industry is geared to the production of ... major biopharmaceutical products. The healthcare market research publisher,s ...
Breaking Medicine Technology:BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
Cached News: